Comprehensive Clinical Characterization of Decade-Long Survivors of Metastatic Breast Cancer

Background: Elucidating the clinical features of metastatic breast cancer (MBC) patients with an exceptionally favorable prognosis may offer insights to improve survival more typical patients. Methods: We collected comprehensive real-world data on clinicopathologic characteristics, treatments, and outcomes 110 consecutive MBC who survived for over ten years from warehouse Samsung Medical Center. Results: The cohort included 54 hormone receptor (HR)-positive/HER2-negative (HR+/HER2−), 21 HR+/HER2+, 16 HR−/HER2+, 14 triple-negative (TNBC) median age at diagnosis was 48.5 years. Approximately 70% initially had a single-organ metastasis. most common site metastasis lung (46.4%), followed by distant lymph nodes (37.3%). During follow-up 14.6 years, duration systemic therapy 11, 8.4, 7.3, 0.8 in HR+/HER2−, TNBC subgroups, respectively. Seven HER2+ received treatment less than two remained treatment-free period, suggesting potential chance cure. subtype (p < 0.001) local curative intent within 1 year = 0.002) were significantly associated long-term survival. patients, but not that HR+/HER2− plateaued approximately 13 after diagnosis. Conclusions: A small subset be curable multimodality therapy. Prospective studies integrating genomic identify unique clinicogenomic can achieve durable disease control without prolonged chemotherapy.